Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence.

Tharaka Dassanayake, Patricia Michie, Gregory Carter, Alison Jones
Author Information
  1. Tharaka Dassanayake: School of Psychology, The University of Newcastle, Newcastle, New South Wales, Australia. Tharaka.Dassanayake@newcastle.edu.au

Abstract

BACKGROUND: Many individuals in the community are prescribed psychoactive drugs with sedative effects. These drugs may affect their daily functions, of which automobile driving is a major component.
OBJECTIVE: To examine the association of three classes of commonly used psychoactive drugs (viz. benzodiazepines and newer non-benzodiazepine hypnotics, antidepressants and opioids) with (i) the risk of traffic accidents (as indexed by epidemiological indicators of risk); and (ii) driving performance (as indexed by experimental measures of driving performance).
METHODS: A literature search for material published in the English language between January 1966 and January 2010 in PubMed and EMBASE databases was combined with a search for other relevant material referenced in the retrieved articles. Retrieved articles were systematically reviewed, carrying out meta-analyses where possible. Twenty-one epidemiological studies (13 case-control and 8 cohort studies) fulfilled the inclusion criteria by estimating the accident risk associated with drug exposure (ascertained by blood/urine analysis or prescription records). Sixty-nine experimental studies fulfilled the inclusion criteria by testing actual or simulated driving performance after administering a single dose or multiple doses.
RESULTS: Two meta-analyses showed that benzodiazepines are associated with a 60% (for case-control studies: pooled odds ratio [OR] 1.59; 95% CI 1.10, 2.31) to 80% (for cohort studies: pooled incidence rate ratio 1.81; 95% CI 1.35, 2.43) increase in the risk of traffic accidents and a 40% (pooled OR 1.41; 95% CI 1.03, 1.94) increase in 'accident responsibility'. Co-ingestion of benzodiazepines and alcohol was associated with a 7.7-fold increase in the accident risk (pooled OR 7.69; 95% CI 4.33, 13.65). Subgroup analysis of case-control studies showed a lower benzodiazepine-associated accident risk in elderly (>65 years of age) drivers (pooled OR 1.13; 95% CI 0.97, 1.31) than in drivers <65 years of age (pooled OR 2.21; 95% CI 1.31, 3.73), a result consistent with age-stratified risk differences reported in cohort studies. Anxiolytics, taken in single or multiple doses during the daytime, impaired driving performance independent of their half-lives. With hypnotics, converging evidence from experimental and epidemiological studies indicates that diazepam, flurazepam, flunitrazepam, nitrazepam and the short half-life non-benzodiazepine hypnotic zopiclone significantly impair driving, at least during the first 2-4 weeks of treatment. The accident risk was higher in the elderly (>65 years of age) who use tricyclic antidepressants (TCAs); however, the evidence for an association of antidepressants with accident risk in younger drivers was equivocal. Sedative but not non-sedative antidepressants were found to cause short-term impairment of several measures of driving performance. Limited epidemiological research reported that opioids may be associated with increased accident risk in the first few weeks of treatment.
CONCLUSIONS: Benzodiazepine use was associated with a significant increase in the risk of traffic accidents and responsibility of drivers for accidents. The association was more pronounced in the younger drivers. The accident risk was markedly increased by co-ingestion of alcohol. Driving impairment was generally related to plasma half-lives of hypnotics, but with notable exceptions. Anxiolytics, with daytime dosing, impaired driving independent of their half-lives. TCAs appeared to be associated with increased accident risk, at least in the elderly, and caused short-term impairment in driving performance. Opioid users may be at a higher risk of traffic accidents; however, experimental evidence is limited on their effects on driving.

References

  1. J Clin Psychiatry. 2005;66 Suppl 2:9-13 [PMID: 15762814]
  2. Eur J Clin Pharmacol. 2000 Sep;56(6-7):453-8 [PMID: 11049006]
  3. J Psychopharmacol. 2002 Dec;16(4):345-54 [PMID: 12503834]
  4. Psychopharmacology (Berl). 1977 Nov 24;55(1):9-12 [PMID: 414266]
  5. Eur J Clin Pharmacol. 1990;39(1):83-7 [PMID: 1980464]
  6. Neuropsychopharmacology. 2002 Aug;27(2):260-9 [PMID: 12093599]
  7. J Clin Psychiatry. 2008 Dec;69(12):1880-6 [PMID: 19203476]
  8. Pain Med. 2004 Mar;5(1):42-9 [PMID: 14996236]
  9. Accid Anal Prev. 2007 Sep;39(5):1050-5 [PMID: 17854578]
  10. Acta Psychiatr Scand Suppl. 1983;308:141-6 [PMID: 6230888]
  11. Neuropsychobiology. 1995;31(2):81-8 [PMID: 7760989]
  12. Psychopharmacology Suppl. 1984;1:182-92 [PMID: 6147840]
  13. Curr Drug Saf. 2007 Sep;2(3):220-6 [PMID: 18690971]
  14. Lancet. 1998 Oct 24;352(9137):1331-6 [PMID: 9802269]
  15. Br J Clin Pharmacol. 1995 Apr;39(4):397-404 [PMID: 7640146]
  16. Am J Epidemiol. 2000 Sep 1;152(5):424-31 [PMID: 10981455]
  17. Psychopharmacology (Berl). 2001 Mar 1;154(2):189-97 [PMID: 11314681]
  18. Acta Psychiatr Scand Suppl. 1986;332:112-8 [PMID: 2883818]
  19. Pharmacol Toxicol. 1994 Aug;75(2):91-8 [PMID: 7971743]
  20. Am J Public Health. 1981 Dec;71(12):1399-400 [PMID: 7316007]
  21. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):45-55 [PMID: 6130073]
  22. Psychopharmacology (Berl). 2009 Dec;207(3):461-7 [PMID: 19798483]
  23. Acta Pharmacol Toxicol (Copenh). 1986 Mar;58(3):182-6 [PMID: 3716812]
  24. Am J Epidemiol. 1992 Oct 1;136(7):873-83 [PMID: 1442753]
  25. J Clin Psychopharmacol. 2009 Oct;29(5):432-8 [PMID: 19745642]
  26. Accid Anal Prev. 2000 Sep;32(5):623-32 [PMID: 10908134]
  27. Pharmacopsychiatry. 1984 Mar;17(2):36-43 [PMID: 6145169]
  28. J Clin Psychopharmacol. 2002 Dec;22(6):576-83 [PMID: 12454557]
  29. Acta Psychiatr Scand Suppl. 1986;332:95-104 [PMID: 3554901]
  30. J Clin Psychiatry. 2003 Jan;64(1):20-9 [PMID: 12590619]
  31. J Clin Psychiatry. 2005 Apr;66(4):436-43 [PMID: 15816785]
  32. Drug Alcohol Depend. 1993 Jun;33(1):19-22 [PMID: 8103737]
  33. Epidemiology. 1994 Nov;5(6):591-8 [PMID: 7841240]
  34. J Psychopharmacol. 2006 Nov;20(6):782-8 [PMID: 16401650]
  35. Br J Clin Pharmacol. 1984;18 Suppl 1:121S-129S [PMID: 6525328]
  36. Br Med J (Clin Res Ed). 1982 Sep 25;285(6345):852 [PMID: 6126244]
  37. Psychopharmacology (Berl). 1981;73(4):340-4 [PMID: 6789355]
  38. Sleep Med. 2003 Nov;4(6):553-61 [PMID: 14607350]
  39. Ann Epidemiol. 1995 May;5(3):239-44 [PMID: 7606314]
  40. Br Med J. 1980 Nov 15;281(6251):1309-12 [PMID: 7437776]
  41. Clin Neuropharmacol. 1994;17 Suppl 1:S9-18 [PMID: 7954488]
  42. Accid Anal Prev. 2004 Mar;36(2):239-48 [PMID: 14642878]
  43. Clin Pharmacol Ther. 1974 Apr;15(4):368-73 [PMID: 4595291]
  44. J Clin Psychiatry. 2009 Mar;70(3):370-7 [PMID: 19192466]
  45. Br J Clin Pharmacol. 1980 Aug;10(2):145-50 [PMID: 6107116]
  46. Clin Pharmacol Ther. 2009 Jun;85(6):596-9 [PMID: 19279562]
  47. Br Med J. 1979 Apr 7;1(6168):917-9 [PMID: 35267]
  48. Traffic Inj Prev. 2008 Oct;9(5):404-13 [PMID: 18836950]
  49. Int Clin Psychopharmacol. 1988 Apr;3(2):157-65 [PMID: 3397523]
  50. J Am Geriatr Soc. 2006 Jan;54(1):77-84 [PMID: 16420201]
  51. Br J Clin Pharmacol. 1979;7 Suppl 1:85S-90S [PMID: 35213]
  52. Psychiatry Clin Neurosci. 2008 Oct;62(5):610-6 [PMID: 18950383]
  53. Psychopharmacology (Berl). 2007 May;191(4):951-9 [PMID: 17219217]
  54. Psychopharmacology (Berl). 2005 Oct;181(4):790-8 [PMID: 16025317]
  55. Sleep Med. 2008 Dec;9(8):818-22 [PMID: 18226959]
  56. Science. 1969 Mar 28;163(3874):1467-8 [PMID: 5773113]
  57. Hum Psychopharmacol. 2008 Jul;23(5):385-97 [PMID: 18350566]
  58. Hum Psychopharmacol. 2008 Dec;23(8):693-705 [PMID: 18763235]
  59. Int J Clin Pharmacol Res. 1983;3(5):323-9 [PMID: 6678826]
  60. Int J Environ Res Public Health. 2009 Mar;6(3):1041-54 [PMID: 19440432]
  61. CNS Drugs. 2004;18(5):297-328 [PMID: 15089115]
  62. Psychopharmacology (Berl). 1977 Mar 23;52(1):103-6 [PMID: 15295]
  63. Accid Anal Prev. 2004 Jul;36(4):631-6 [PMID: 15094417]
  64. J Clin Psychiatry. 2008 Jul;69(7):1099-103 [PMID: 18588362]
  65. Br J Clin Pharmacol. 1977 Oct;4(5):573-8 [PMID: 20918]
  66. Am J Epidemiol. 2009 Mar 15;169(6):761-8 [PMID: 19181876]
  67. JAMA. 1997 Jul 2;278(1):27-31 [PMID: 9207334]
  68. Sleep. 2002 Mar 15;25(2):224-31 [PMID: 11905433]
  69. Science. 1982 Jul 2;217(4554):79-81 [PMID: 7089544]
  70. J Clin Psychiatry. 2009 Apr 21;70(5):663-73 [PMID: 19389334]
  71. Clin J Pain. 2006 Jun;22(5):499-504 [PMID: 16772806]
  72. Psychopharmacology (Berl). 1999 Apr;143(4):373-9 [PMID: 10367554]
  73. Forensic Sci Int. 2003 Apr 23;133(1-2):79-85 [PMID: 12742692]
  74. J Sleep Res. 2009 Dec;18(4):387-96 [PMID: 19552733]
  75. Eur Neuropsychopharmacol. 1995 Mar;5(1):35-42 [PMID: 7613099]
  76. Accid Anal Prev. 1989 Aug;21(4):341-53 [PMID: 2669785]
  77. Ann Epidemiol. 2007 Aug;17(8):597-602 [PMID: 17574863]
  78. Neurosci Biobehav Rev. 1995 Fall;19(3):479-93 [PMID: 7566749]
  79. Int J Clin Pharmacol Ther. 2002 Jul;40(7):304-9 [PMID: 12139207]
  80. J Clin Psychopharmacol. 1998 Jun;18(3):212-21 [PMID: 9617980]
  81. J Clin Psychopharmacol. 1992 Apr;12(2):86-95 [PMID: 1573045]
  82. Psychopharmacology (Berl). 2006 Jan;183(4):462-70 [PMID: 16292592]
  83. Hum Psychopharmacol. 2008 Jul;23(5):399-407 [PMID: 18383000]
  84. Psychopharmacology (Berl). 2001 Apr;154(4):356-61 [PMID: 11349388]
  85. J Clin Psychopharmacol. 1995 Feb;15(1):30-40 [PMID: 7714226]

MeSH Term

Accidents, Traffic
Analgesics, Opioid
Antidepressive Agents
Automobile Driving
Benzodiazepines
Epidemiologic Studies
Female
Humans
Male
Research Design
Risk Factors
Risk-Taking

Chemicals

Analgesics, Opioid
Antidepressive Agents
Benzodiazepines

Word Cloud

Created with Highcharts 10.0.0riskdriving1accidentperformancestudiesassociatedpooled95%CIantidepressantsaccidentsepidemiologicalexperimentaldriversbenzodiazepinestrafficincreaseORevidencedrugsmayassociationhypnoticsopioids13case-controlcohort231elderlyyearsagehalf-livesimpairmentincreasedpsychoactiveeffectsnon-benzodiazepineindexedmeasuressearchmaterialJanuaryarticlesmeta-analysesfulfilledinclusioncriteriaanalysissinglemultipledosesshowedstudies:ratioalcohol7>65reportedAnxiolyticsdaytimeimpairedindependentleastfirstweekstreatmenthigheruseTCAshoweveryoungershort-termBACKGROUND:ManyindividualscommunityprescribedsedativeaffectdailyfunctionsautomobilemajorcomponentOBJECTIVE:examinethreeclassescommonlyusedviznewerindicatorsiiMETHODS:literaturepublishedEnglishlanguage19662010PubMedEMBASEdatabasescombinedrelevantreferencedretrievedRetrievedsystematicallyreviewedcarryingpossibleTwenty-one8estimatingdrugexposureascertainedblood/urineprescriptionrecordsSixty-ninetestingactualsimulatedadministeringdoseRESULTS:Two60%odds[OR]591080%incidencerate81354340%410394'accidentresponsibility'Co-ingestion7-fold6943365Subgrouplowerbenzodiazepine-associated097<6521373resultconsistentage-stratifieddifferencestakenconvergingindicatesdiazepamflurazepamflunitrazepamnitrazepamshorthalf-lifehypnoticzopiclonesignificantlyimpair2-4tricyclicequivocalSedativenon-sedativefoundcauseseveralLimitedresearchCONCLUSIONS:Benzodiazepinesignificantresponsibilitypronouncedmarkedlyco-ingestionDrivinggenerallyrelatedplasmanotableexceptionsdosingappearedcausedOpioiduserslimitedEffectsdriving:systematicreviewmeta-analysis

Similar Articles

Cited By